- Home
- REFI vs PRQR Comparison
REFI vs PRQR Comparison
Compare REFI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | PRQR |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 250.7M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | REFI | PRQR |
|---|---|---|
| Price | $11.98 | $2.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $20.00 | $8.14 |
| AVG Volume (30 Days) | 165.0K | ★ 586.4K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 16.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $54,287,847.00 | $18,859,556.00 |
| Revenue This Year | $13.78 | N/A |
| Revenue Next Year | $4.07 | $19.56 |
| P/E Ratio | $7.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.85 | $1.07 |
| 52 Week High | $16.27 | $3.10 |
Technical Indicators
Market Signals| Indicator | REFI | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 34.00 | 51.88 |
| Support Level | $12.15 | $1.92 |
| Resistance Level | $12.45 | $2.31 |
| Average True Range (ATR) | 0.26 | 0.15 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 0.74 | 66.71 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.